Core Viewpoint - Shanghai Xuantai Pharmaceutical Technology Co., Ltd. has successfully renewed the inclusion of its product, Sitagliptin Metformin Extended-Release Tablets (II), in the National Medical Insurance Catalog (2025), reflecting the recognition of its clinical value by the National Healthcare Security Administration [1][2]. Group 1: Product Information - The product Sitagliptin Metformin Extended-Release Tablets (II) has been included in the National Medical Insurance Catalog (2025) under a national negotiation renewal format [1]. - The inclusion is expected to enhance the affordability and accessibility of the drug for patients, thereby promoting its market expansion and increasing sales volume [1]. Group 2: Impact on the Company - The renewal of the product's inclusion in the National Medical Insurance Catalog is anticipated to have a positive impact on the company's long-term operational development [1]. - The company plans to actively cooperate in implementing the medical insurance policy to benefit more patients [1]. Group 3: Implementation Timeline - The National Medical Insurance Catalog (2025) will officially take effect on January 1, 2026, with specific details on reimbursement standards and policies to be announced by relevant government departments [2].

Core Viewpoint - Shanghai Xuantai Pharmaceutical Technology Co., Ltd. has successfully renewed the inclusion of its product, Sitagliptin Metformin Extended-Release Tablets (II), in the National Medical Insurance Directory, which is expected to positively impact the company's long-term operational development despite short-term performance uncertainties [1]. Group 1: Stock Performance - As of December 8, 2025, Xuantai Pharmaceutical (688247) closed at 10.37 yuan, up 0.39% from the previous trading day, with a total market capitalization of 4.701 billion yuan [1]. - The stock opened at 10.36 yuan, reached a high of 10.4 yuan, and a low of 10.3 yuan, with a trading volume of 18.4461 million yuan and a turnover rate of 0.39% [1]. Group 2: Product and Market Impact - The renewed agreement maintains the medical insurance payment standard at 3.47 yuan per tablet, effective from January 1, 2026, to December 31, 2027 [1]. - The product is classified as an oral compound hypoglycemic agent and falls under Category B, which is expected to enhance drug accessibility and market promotion [1].

Core Viewpoint - The company announced that its product, Sitagliptin Metformin Extended-Release Tablets (II), has been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025) through a national negotiation renewal [1] Group 1 - The inclusion of Sitagliptin Metformin Extended-Release Tablets (II) in the national drug list is a significant development for the company [1]

Core Viewpoint - XuanTai Pharmaceutical (688247.SH) has successfully renewed the inclusion of its product, Sitagliptin Metformin Extended-Release Tablets (II), in the National Medical Insurance Catalog (2025) through a national negotiation process, indicating recognition of the drug's clinical value by the National Healthcare Security Administration [1] Summary by Relevant Categories Product Inclusion - The Sitagliptin Metformin Extended-Release Tablets (II) have been renewed for inclusion in the National Medical Insurance Catalog, reflecting the government's acknowledgment of its clinical value [1] Market Impact - The inclusion in the insurance catalog is expected to enhance the affordability and accessibility of the drug for patients, which will facilitate market promotion and increase sales scale [1] Long-term Development - This development is viewed positively for the company's long-term operational growth, as it aligns with the goal of benefiting more patients through improved healthcare policies [1]